Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 1034

BillFederalHouseIn Committee
Phair Pricing Act of 2019
About This Bill
Committee
Latest Action · February 7, 2019
Referred to the Subcommittee on Health.
Congress
116th (2019–2021)
Introduced
February 7, 2019
Cosponsors (77)
18D 59R
View PDF ↗

Summary

Highlight any text to annotate
Phair Pricing Act of 2019 This bill requires that certain negotiated prices for covered drugs under the Medicare prescription drug benefit be disclosed at the point-of-sale. Specifically, negotiated prices offered under a prescription drug plan (PDP) must be disclosed at the point-of-sale; the disclosed price must include specified adjustments, payments, and fees that are negotiated with the pharmacy (e.g., dispensing fees) by the PDP sponsor or pharmacy benefit manager. Additionally, the Centers for Medicare & Medicaid Services must establish certain quality measures for PDP sponsors to use when determining incentive payments and adjustments (e.g., performance payments) to pharmacies.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.